文献速递胸部肿瘤放疗

同步整合减量放疗对比常规分割放疗联合化疗治疗局限期小细胞肺癌:3期随机临床试验(SDR-RT试验)

Simultaneous Integrated Dose Reduction Radiation Therapy Versus Conventional Fractionated Radiation Therapy With Chemotherapy for Limited-Stage Small Cell Lung Cancer in the Modern Treatment Era: A Phase 3, Randomized Clinical Trial (SDR-RT trial).
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2025-10-14

该3期随机试验纳入336例局限期小细胞肺癌患者,1:1随机接受同步整合减量放疗(SDR-RT,CTV 50 Gy、GTV 60 Gy/28次)或常规分割放疗(CF-RT,CTV与GTV均60 Gy/30次)联合4–6周期化疗。SDR-RT急性≥3级毒性和放射性肺炎发生率更低。

核心结论

  • 与CF-RT相比,SDR-RT在局限期小细胞肺癌中取得相似生存且急性不良事件更少,可视为更具保护性的治疗方式。

研究设计与样本

  • 3期随机临床试验,2017年2月至2023年3月纳入336例局限期小细胞肺癌患者,1:1随机接受SDR-RT(n=165)或CF-RT(n=171)联合4–6周期化疗。
  • CF-RT方案为CTV与GTV均60 Gy/30次、每日1次、共6周;SDR-RT方案为CTV 50 Gy、GTV 60 Gy/28次、每日1次、共5.5周。
  • 主要终点为意向治疗人群的无进展生存率,次要终点为总生存率和不良事件发生率。

主要发现

  • 两组总生存、局部区域PFS和局部区域复发率差异无统计学意义。

关键数值与推荐

  • SDR-RT:CTV 50 Gy、GTV 60 Gy,28次,每日1次,共5.5周,联合4–6周期化疗。
  • CF-RT:CTV与GTV均60 Gy,30次,每日1次,共6周,联合4–6周期化疗。

临床怎么用

  • 对局限期小细胞肺癌行根治性放化疗时,可考虑SDR-RT(CTV 50 Gy、GTV 60 Gy/28次)以降低急性毒性和放射性肺炎,同时保持相似生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Simultaneous integrated dose reduction (SDR) radiation therapy (SDR-RT) with a definitive dose to the gross tumor volume (GTV) and a relatively lower dose to the clinical target volume (CTV) might be beneficial in improving normal tissue sparing with low toxicity. We aimed to compare the efficacies of SDR-RT and conventional fractionated radiation therapy (CF-RT) for limited-stage small cell lung cancer (LS-SCLC). METHODS AND MATERIALS: Eligible patients with LS-SCLC were 1:1 randomized to receive CF-RT (60 Gy in 30 once-daily fractions over 6 weeks for both CTV and GTV) or SDR-RT (50 Gy for CTV and 60 Gy for GTV in 28 once-daily fractions over 5.5 weeks) along with 4 to 6 cycles of chemotherapy. The primary endpoint was progression-free survival (PFS) rate in the intention-to-treat population, whereas the secondary endpoints were overall survival rate and adverse event incidence. RESULTS: Between February 2017 and March 2023, 336 patients randomly received either SDR-RT (n = 165) or CF-RT (n = 171). Over a median follow-up of 56 months, the 2- and 5-year PFS rates in the intention-to-treat analysis were, respectively, 42.0% and 31.9% with SDR-RT, and 40.7% and 30.5% with CF-RT (P = .015 for noninferiority). The between-group differences in overall survival, locoregional PFS, and locoregional recurrence rates were nonsignificant. Compared with CF-RT, SDR-RT was associated with lower median values of V20 (21.0% vs 22.8%) and Dmean (12.1 vs 13.4 Gy) of the bilateral lungs (both P < .001). Acute grade ≥3 toxicities and radiation pneumonitis incidence were lower with SDR-RT than that with CF-RT (54.5% vs 66.9%, P = .020; 2.4% vs 7.7%, P = .027). CONCLUSIONS: Compared with CF-RT, SDR-RT led to similar survival and less acute adverse events. SDR-RT may be considered as a more protective approach for LS-SCLC treatment.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Zhan TY, Zhang T, Wang WQ, et al. Simultaneous Integrated Dose Reduction Radiation Therapy Versus Conventional Fractionated Radiation Therapy With Chemotherapy for Limited-Stage Small Cell Lung Cancer in the Modern Treatment Era: A Phase 3, Randomized Clinical Trial (SDR-RT trial). Int J Radiat Oncol Biol Phys. 2025. PMID: 41101556. doi:10.1016/j.ijrobp.2025.09.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。